The primary sources of particulate matter are linked to human activity. Certain particulate emissions, particularly those of a finer nature, can significantly impact human health, making them one of the most concerning pollutants. Ultrafine particles (UFP), which have a diameter of less than 100 nm, are of particular concern due to their impact on human health and the difficulty in controlling them. The concentration of ultrafine particles (UFP) in the workplace is a growing concern and is classified as an emerging risk. Workers may be exposed to UFP through inhalation, skin absorption, ingestion, or a combination of these routes. This study aims to determine the levels of UFP exposure among workers in environments with varying direct particle emission patterns. Measurements were conducted to compare the results with the levels recommended by the WHO. The study monitored industrial workplaces with direct particulate matter emissions, such as a carpentry and a bakery, as well as social sector sites without or almost without direct particle emissions, such as a school and a health clinic. One conclusion drawn from this study is that all tasks and occupations are susceptible to high levels of UFP, exceeding WHO recommended values in virtually all monitored environments. Therefore, monitoring and controlling UFP is crucial. Further in-depth studies on this subject are also necessary..

Angiogenesis is a process whereby new blood vessels are born from preexistent ones, which has a role in transporting oxygen and nutrients. On the other hand, inhibiting this process is a strategy used to treat some diseases, including cancers, diabetic retinopathy, and rheumatoid arthritis. This study investigates the effect of a new nutraceutical (Terasen®) on angiogenesis. Terasen® is made from a standardized extract of Euterpe oleraceae (Açaí), Myrciaria dubia (Camu-Camu), and purified oil of Bixa orellana (Annatto) and Astrocaryum aculeatum (Tucumã). The in vivo angiogenesis model used was the chorioallantoic membrane (CAM) from chicken embryos. The embryos were divided into seven groups: a vehicle control treated with ethanol solution (ETH), a naïve control treated only with saline solution (SOR), a positive control treated with dexamethasone (DEX), and four groups treated with Terasen® at different concentrations (0.5, 1, 2, and 3 mg/ml). The parameters assessed were the vessels’ area, length, and amount. The results show a statistically significant and concentration-dependent inhibition of angiogenesis caused by Terasen®. Our results suggest the nutraceutical has a high antiangiogenesis potential, possibly due to its bioactive compounds, including anthocyanins, quercetin, and tocotrienols.